Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BioLineRx Ltd. A biopharmaceutical firm developing and commercializing therapies for oncology and rare diseases.	United States of America	BLRX
BIOMARIN PHARMACEUTICAL INC Develops and commercializes therapies for rare, life-threatening genetic diseases.	United States of America	BMRN
BioMaxima S.A. Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.	Poland	BMX
Biomea Fusion, Inc. Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.	United States of America	BMEA
BIOMERICA INC Develops diagnostic tests for GI, inflammatory diseases, and diabetes for lab and at-home use.	United States of America	BMRA
bioMérieux Provides in vitro diagnostic solutions for clinical and industrial microbiology.	France	BIM
BiomX Inc. Develops phage therapies to target harmful bacteria in chronic diseases like cystic fibrosis.	United States of America	PHGE
BioNTech SE Pioneering mRNA immunotherapies and vaccines to combat cancer and infectious diseases.	United States of America	BNTX
BioPorto IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.	Denmark	BIOPOR
BioRestorative Therapies, Inc. A clinical-stage company developing stem cell therapies for pain, metabolic disorders, and aesthetics.	United States of America	BRTX